TY - JOUR
T1 - Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic
AU - Chien, Yu Wen
AU - Klugman, Keith P.
AU - Morens, David M.
N1 - Funding Information:
Received 10 April 2010; accepted 29 June 2010; electronically published 28 October 2010. Potential conflicts of interest: K.P.K. has received consultant fees and research support from Pfizer Vaccines and GlaxoSmithKline but received no funding from industry for this analysis. All other authors report no potential conflicts of interest. Presented in part: 7th International Symposium on Pneumococci and Pneumococcal Disease, Tel Aviv, Israel, 14–18 March 2010 (oral presentation). Financial support: none reported. Reprints or correspondence: Dr Klugman, Rollins School of Public Health, 1518 Clifton Rd, Atlanta, GA 30322 (kklugma@emory.edu).
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Background. Most deaths in the 1918 influenza pandemic were caused by secondary bacterial pneumonia. Methods. We performed a systematic review and reanalysis of studies of bacterial vaccine efficacy (VE) in preventing pneumonia and mortality among patients with influenza during the 1918 pandemic. Results. A meta-analysis of 6 civilian studies of mixed killed bacterial vaccines containing pneumococci identified significant heterogeneity among studies and estimated VE at 34% (95% confidence interval [CI], 19%-47%) in preventing pneumonia and 42% (95% CI, 18%-59%) in reducing case fatality rates among patients with influenza, using random-effects models. Using fixed-effect models, the pooled VE from 3 military studies was 59% (95% CI, 43%-70%) for pneumonia and 70% (95% CI, 50%-82%) for case fatality. Military studies showed less heterogeneity and may provide more accurate results than civilian studies, given the potential biases in the included studies. Findings of 1 military study using hemolytic streptococci also suggested that there was significant protection. Conclusions. Despite significant methodological problems, the systematic biases in these studies do not exclude the possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to multiple pneumococcal serotypes and that bacterial vaccines may play a role in preventing influenza-associated pneumonia.
AB - Background. Most deaths in the 1918 influenza pandemic were caused by secondary bacterial pneumonia. Methods. We performed a systematic review and reanalysis of studies of bacterial vaccine efficacy (VE) in preventing pneumonia and mortality among patients with influenza during the 1918 pandemic. Results. A meta-analysis of 6 civilian studies of mixed killed bacterial vaccines containing pneumococci identified significant heterogeneity among studies and estimated VE at 34% (95% confidence interval [CI], 19%-47%) in preventing pneumonia and 42% (95% CI, 18%-59%) in reducing case fatality rates among patients with influenza, using random-effects models. Using fixed-effect models, the pooled VE from 3 military studies was 59% (95% CI, 43%-70%) for pneumonia and 70% (95% CI, 50%-82%) for case fatality. Military studies showed less heterogeneity and may provide more accurate results than civilian studies, given the potential biases in the included studies. Findings of 1 military study using hemolytic streptococci also suggested that there was significant protection. Conclusions. Despite significant methodological problems, the systematic biases in these studies do not exclude the possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to multiple pneumococcal serotypes and that bacterial vaccines may play a role in preventing influenza-associated pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=78649540297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649540297&partnerID=8YFLogxK
U2 - 10.1086/657144
DO - 10.1086/657144
M3 - Article
C2 - 21028954
AN - SCOPUS:78649540297
SN - 0022-1899
VL - 202
SP - 1639
EP - 1648
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -